Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
IBRX
IBRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IBRX News
Federal Reserve's Policy Decision Draws Attention
3d ago
stocktwits
Investment Recommendations for Cava, Immunitybio, and Trulieve
3d ago
CNBC
GT Biopharma Advances Three Drug Candidates into Clinical Trials
Jun 08 2026
Globenewswire
GT Biopharma Advances Three Cancer Drug Candidates into Clinical Trials
Jun 08 2026
Newsfilter
Challenges and Opportunities in Neuro-Oncology
Jun 03 2026
Newsfilter
ImmunityBio Showcases ANKTIVA® Research at ASCO Meeting
Jun 01 2026
Newsfilter
GT Biopharma: Three Drugs Enter Human Trials
May 29 2026
PRnewswire
GT Biopharma Advances Three Drug Candidates in Clinical Trials
May 29 2026
Newsfilter
ImmunityBio Receives FDA Review for ANKTIVA Application
May 28 2026
Yahoo Finance
Multiple Companies Face Class Action Lawsuits
May 26 2026
Globenewswire
ImmunityBio Faces Securities Class Action Lawsuit
May 26 2026
PRnewswire
Reminder for ImmunityBio Securities Class Action
May 25 2026
Globenewswire
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
May 25 2026
Globenewswire
ImmunityBio Faces Class Action Lawsuit Reminder
May 25 2026
Globenewswire
ImmunityBio Faces Class Action Lawsuit for Securities Violations
May 24 2026
Globenewswire
Reminder of ImmunityBio Securities Class Action
May 23 2026
PRnewswire
Show More News
